Compounded Peptides ·
The tirzepatide shortage officially began in December 2022 when rapidly rising demand for Mounjaro outstripped Eli Lilly's manufacturing capacity. FDA maintained tirzepatide on its shortage list through most of 2023 and 2024. In October 2024 the agency declared the shortage resolved, setting in motion a series of wind-down deadlines for compounders. A federal court challenge by the Outsourcing Facilities Association temporarily delayed enforcement, but by early 2025 the legal questions were substantially resolved in FDA's favor. Throughout 2025 and into early 2026 the agency has maintained that compounded tirzepatide is no longer subject to shortage-based enforcement discretion.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.